Trade Summary

3 days ago, Torley Helen, serving as Pres, CEO at Halozyme Therapeutics, Inc. (HALO), sold 50,000 shares at $68.68 per share, for a total transaction value of $3,433,875.00. Following this transaction, Torley Helen now holds 767,780 shares of HALO.

This sale represents a 6.00% decrease in Torley Helen's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, May 11, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, May 13, 2026, 2 days after the trade was made.

Halozyme Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.